Bosentan

Drug Profile

Bosentan

Alternative Names: ACT-050088; Bosentan monohydrate; RO-470203; RO-470203-029; Tracleer

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Actelion Pharmaceuticals
  • Class Antihypertensives; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Skin ulcer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Skin ulcer
  • No development reported Diabetic foot ulcer
  • Discontinued Asthma; Heart failure; Inflammatory bowel diseases; Ischaemic heart disorders; Kidney disorders; Malignant melanoma; Myocardial infarction; Pulmonary fibrosis; Reperfusion injury; Transplant rejection

Most Recent Events

  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
  • 08 Nov 2016 Launched for Skin ulcer in Japan (PO)
  • 30 Sep 2016 Actelion Pharmaceuticals completes a phase-III clinical trial in Pulmonary arterial hypertension (In adolescents, In children, In infants, In neonates) in Japan (PO) (Japic-CTI132155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top